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Abstract
Background. Immunoglobulin A nephropathy (IgAN) is
the most common form of glomerulonephritis, and many
patients are at risk of at least slow progression. However,
prediction of the renal outcome in individual patients re-
mains difficult.
Methods. To develop a practical and user-friendly scheme
for risk stratification of IgAN patients, data were extracted
from a prospective cohort study conducted in 97 clinical
units in Japan from 1995. Specifically, we examined dete-
rioration in renal function, defined as doubling of serum
creatinine, within 10 years of follow-up in 790 adult IgAN
patients without substantial renal dysfunction at baseline
using a decision tree induction algorithm.
Results. Recursive partitioning indicated that the best sin-
gle predictor of renal deterioration was severe proteinuria
on urine dipstick testing, followed by hypoalbuminaemia
and the presence of mild haematuria for patients with
and without severe proteinuria, respectively. Serum total
protein levels, diastolic blood pressure and histological
grade were placed in the third tier of the decision tree
model. With these six variables, patients can be readily
stratified into seven risk groups whose incidence of re-
nal deterioration within 10-year follow-up ranges from
1.0% to 51.4%. Logistic regression also identified se-
vere proteinuria, hypoalbuminaemia and mild haematuria
as significant predictors of deterioration. Areas under the
receiver-operating characteristic curve for the prediction
were comparable between the decision tree model and the
logistic regression model [0.830 (95% confidence inter-
val, 0.777–0.883) versus 0.808 (95% confidence interval,
0.754–0.861)].
Conclusion.RiskofsubstantialrenaldeteriorationinIgAN
patients can be validly estimated using six predictors ob-
tained from clinical routine.
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Introduction
Immunoglobulin A nephropathy (IgAN) was described as
a new clinical entity in 1968 by Berger and Hinglais [1]
and is now the most common cause of idiopathic glomeru-
lonephritis [2–4]. Many studies have evaluated long-term
outcomes and prognostic factors of patients with IgAN. Al-
though this disorder is thought to follow a benign course,
many patients are at risk for at least slow progression.
Furthermore, end-stage renal disease (ESRD) develops in
∼15% of cases within 10 years [5]. Several prognostic fac-
tors, such as elevated serum creatinine, severe proteinuria,
arterial hypertension and histological findings from a renal
biopsy, were suggested in the previous studies [5].
Predicting renal outcome in individual patients offers
great benefits on determining those who need aggressive
therapeuticregimen.Weearlierreportedavalidscoringsys-
tem to predict renal outcome in IgAN on the basis of our
7-year follow-up data including all patients followed up
with various levels of baseline renal function [6]. Although
the estimation was accurate, it was somewhat complex be-
cause many predictors were involved with their meticulous
classification levels. Additionally, clinicians already know
that the patients with azotaemia at their initial visit have
a poor renal outcome from their own clinical experiences.
The objectives of the current analysis are, therefore, to de-
velop a practical and user-friendly decision tree scheme
to stratify the risks of progression of the disease within
10 years of follow-up among biopsy-proven IgAN patients
without substantial renal dysfunction.
Methods
Measurement and follow-up of study subjects
Our earlier study [6] proposed a scoring system to pre-
dict renal outcome in IgAN based on the follow-up data
C   The Author [2008].
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until 2002, 7 years from the beginning of the follow-up.
The methods of subject inclusion have been described in
the same article. Briefly, 2450 patients with biopsy-proven
IgAN from 97 clinical units were followed from 1995 when
a nationwide survey on IgAN was jointly conducted by the
two research committees on specified intractable diseases
organized by the Japanese Government. Follow-up mail
surveys to collect information on outcomes such as death,
ESRD and serum creatinine were conducted in 1997, 1999,
2002 and 2005 with response rates of 82.5, 95.7, 93.3 and
82.7%, respectively.
The current analysis excluded patients <13 years of age
because the glomerular filtration rate (GFR) was estimated
usingtheabbreviatedModificationofDietinRenalDisease
(MDRD) study equation formulated using data from adults
[7] and not validated among children. We also excluded
patients whose estimated baseline GFR was <60 mL/min/
1.73 m2, and whose serum creatinine was not measured
during the latter half of the follow-up period unless they
reached the endpoint, substantial renal deterioration.
The baseline data of the patients obtained by reviewing
medical records in the nationwide survey in 1995 included
sex, age, family history of chronic renal failure and chronic
glomerulonephritis, initial clinical manifestations, year of
diagnostic renal biopsy, systolic and diastolic blood pres-
sure, urine protein and blood, serum total protein, albumin
and creatinine. Proteinuria was semiquantified with a spot
urinedipsticktestwith(−),(±),(+),(++)and(+++)cor-
responding to <10, 10–29, 30–99, 100–299 and ≥300 mg/
dL of urine albumin, respectively. Histological grade at
initial renal biopsy was assessed using the criteria from
the Joint Committee of the Research Group on Progres-
sive Renal Diseases and the Japanese Society of Nephrol-
ogy [8]. For GFR estimation, the abbreviated MDRD
study equation modified for Japanese patients with chronic
kidney disease was applied [9]. The endpoint in the
presentstudywassubstantialdeteriorationinrenalfunction,
which was defined as doubling of serum creatinine within
10 years. However, even if serum creatinine was more than
double the baseline level, the case was not treated as sub-
stantial renal deterioration unless above the normal range,
≥1.1 and ≥0.8 mg/dL in men and women, respectively
[10].
Development of the decision tree model
The classification tree analysis generates groups of indi-
viduals on the basis of a selected criterion, the Gini index,
for splitting a group into two to maximize the probability
of a single outcome, namely substantial renal deterioration
[11,12]. The recursive process of partitioning data con-
tinues until the Gini index indicates that the tree fits the
information contained in the dataset without overfitting. It
can provide a practical model for dichotomous outcomes if
the validity of the obtained model is proved sufficient [13].
The missing values were replaced with values minimizing
the impurity of the nodes, median values for continuous
variables and most frequent categories for categorical vari-
ables, or distribution-based estimates.
We constructed 17 candidate models by changing the de-
tailed settings of model construction, such as the manner of
imputation of the missing values and the minimum size of
the records in parent and final child nodes. Then, the final
model was selected from these candidate models based on
the Gini index and the area under the receiver-operating
characteristic (ROC) curve for the entire dataset. We also
performedasubanalysisforthepatientswhosedataon24-h
urinary protein excretion were available to validate the pre-
diction using dipstick urinalysis.
Evaluation of the decision tree model
The incidence rate of substantial renal deterioration for
each risk group, the odds ratios (ORs) with their 95% con-
fidence intervals (CIs) between risk groups and the area
undertheROCcurveforpredictingrenaldeteriorationwere
calculated. Then, a 5-fold cross-validation was performed
to assess the reproducibility of the decision tree model.
Overestimation in the original sample was evaluated using
thebootstrapinthewholedatasetbysamplingwithreplace-
mentfor100iterations[14,15].Thetreemodelwasfittedto
abootstrapsampletoestimatetheriskofrenaldeterioration
and evaluated in the bootstrap sample and in the original
sample. The performance, the area under the ROC curve in
the bootstrap sample represents estimation of the apparent
performance, and the performance in the original sample
represents test performance. The difference between these
performances is an estimate of the optimism in the ap-
parent performance. To estimate the internally validated
performance, the average of the optimism is subtracted
from the apparent performance. A multivariable logistic
regression model was also constructed, and the accuracy
of the decision tree model was compared with that of the
logistic regression model using the area under the ROC
curves.
Statistics and ethics
Whendemographicandclinicalcharacteristicsandbaseline
laboratory data were compared between patients with and
without renal deterioration, Student’s t-test was used for
continuous variables, and Fisher’s exact test for categorical
variables. Ordinal categories of year of initial renal biopsy,
proteinuriaandhistopathologicalgradeatrenalbiopsywere
replaced by consecutive integers, and the Wilcoxon rank-
sum test was applied.
All tests of significance were 2-tailed, and the P-values
<0.05 were considered statistically significant. Analyses
were performed using the STATA 9.2 software (STATA
Corporation, College Station, TX, USA) and SAS ver-
sion 9.1.2 including Enterprise Miner 5.0 (SAS Institute,
Cary, NC, USA). This investigation was approved by the
Ethics Committee of Kyoto University Graduate School of
Medicine and the Ethics Committee of the Juntendo Uni-
versity School of Medicine.
Results
To obtain a dataset for the current analysis, 165 patients
with unknown outcomes and two patients with erroneous1244 M. Goto et al.
Table 1. Baseline characteristics of patients with or without renal deterioration
Characteristic Patients with renal deterioration Patients with stable renal function P-value
No. of patients 68 722
Follow-up period (month) 90.5 (67–122) 120 (89–122) <0.001
Age (year) 27.7 (21.4–44.1) 28.2 (20.6–40.7) 0.55
Women 34 (50.0) 426 (59.0) 0.096
Family history of chronic renal failure 5 (7.4) 30 (4.2) 0.18
Family history of chronic glomerulonephritis 2 (2.9) 50 (6.9) 0.16
Initial manifestation
Chance proteinuria 54 (79.4) 517 (71.6) 0.11
Macrohaematuria 3 (4.4) 96 (13.3) 0.019
Acute nephritis 5 (7.4) 26 (3.6) 0.12
Nephrosis 3 (4.4) 13 (1.8) 0.15
Others 3 (4.4) 64 (8.9) 0.15
Year of initial renal biopsy
1994–1995 15 (22.1) 151 (21.3)
1992–1993 25 (36.8) 168 (23.7)
1990–1991 7 (10.3) 132 (18.6)
1988–1989 8 (11.8) 102 (14.4)
1987 or before 13 (19.1) 157 (22.1) 0.20
Systolic blood pressure (mmHg) 120 (110–138) 120 (110–130) 0.21
Diastolic blood pressure (mmHg) 74 (68–80) 70 (62–80) 0.21
Proteinuria
(−), (±) 6 (9.4) 286 (41.9)
(+) 12 (18.8) 195 (28.6)
(++) 22 (34.4) 137 (20.1)
(+++) 24 (37.5) 65 (9.5) <0.001
Haematuria, red blood cells/high-power field
None 6 (9.1) 182 (26.5)
1–29 49 (74.2) 388 (56.4)
≥30 11 (16.7) 118 (17.2) 0.002
Serum total protein (g/dL) 6.8 (6.3–7.1) 7.1 (6.8–7.4) <0.001
Serum albumin (g/dL) 4.0 (3.7–4.4) 4.3 (4.1–4.6) <0.001
Glomerular filtration rate (mL/min/1.73 m2) 78.9 (68.8–97.5) 80.4 (69.1–95.3) 0.33
Histological grade of initial renal biopsy
Grade I 10 (15.6) 190 (28.3)
Grade II 21 (32.8) 257 (38.2)
Grade III 28 (43.8) 197 (29.3)
Grade IV 5 (7.8) 28 (4.2) 0.002
Values are expressed as number (percentage) or median (interquartile range).
baseline serum creatinine levels were excluded from the
2450 patients tracked from 1995. Furthermore, 880 pa-
tients with a baseline GFR of 60 mL/min/1.73 m2 or less,
491 patients with missing serum creatinine data during the
latter half of the follow-up period and 122 patients aged
<13 years were also excluded. The remaining 790 patients
were included in the current analysis. The median follow-
up period of these patients was 119.5 months [interquartile
range (IQR), 89–122].
Table 1 summarized demographic and clinical charac-
teristics and baseline laboratory data according to the
presence or absence of deterioration in renal function. A
total of 68 patients (8.6%) lapsed into substantial renal
deterioration, including 23 patients with chronic haemo-
dialysis. Two patients had a doubling of serum creatinine
with the maximum value still in the normal range and
were classified into the stable renal function group. Be-
cause we included patients who reached the endpoint ir-
respective of its point of time, the follow-up period of
the progressive disease group was shorter than that of
the stable disease group. Patients who visited the doc-
tors because of macrohaematuria showed a better renal
outcome. Severe proteinuria, mild haematuria, hypopro-
teinaemia, hypoalbuminaemia and high histopathological
grade at renal biopsy were related to deterioration in renal
function.
Development of the decision tree model
Figure 1 demonstrates the final tree model that has the
smallest Gini index and the largest area under the ROC
curve for predicting renal deterioration among 17 candi-
date models. Of the 14 variables evaluated, the decision
tree induction algorithm identified the amount of protein-
uria as the best discriminator between patients with and
without deterioration in renal function within 10 years of
follow-up. Among those patients with severe proteinuria,
the best predictor of renal deterioration was serum albumin
levels. On the other hand, the presence of mild haematuria
was the best predictor of renal deterioration among those
without severe proteinuria. The serum total protein levels,
diastolic blood pressure and histological grade were se-
lected as the third tier of the stratification for patients with
mild proteinuria and mild haematuria, severe proteinuriaProgression risk of IgA nephropathy 1245
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Fig. 1. Final decision tree model. RD denotes subsequently developing renal deterioration.
and normal range of serum albumin and severe proteinuria
and hypoalbuminaemia, respectively.
The final tree (Figure 1) has branch points that permit
patient stratification into seven risk groups: minimum risk
[urineprotein <100 mg/dL andtheabsence of mildhaema-
turia (1–29 red blood cells/high-power field)], low risk 1
(urine protein <100 mg/dL, the presence of mild haema-
turia and serum total protein ≥6.41 g/dL), low risk 2 (urine
protein ≥100 mg/dL, serum albumin ≥3.95 g/dL and di-
astolic blood pressure <74 mmHg), high risk 1 (urine pro-
tein <100 mg/dL, the presence of mild haematuria and
serum total protein <6.41 g/dL), high risk 2 (urine pro-
tein ≥100 mg/dL, serum albumin ≥3.95 g/dL and dias-
tolic blood pressure ≥74 mmHg), high risk 3 (urine protein
≥100 mg/dL, serum albumin <3.95 g/dL and histological
grade I or II) and very high risk (urine protein ≥100 mg/
dL, serum albumin <3.95 g/dL and histological grade III
or IV). Actual incidences of substantial renal deterioration
were 1.0% (2 of 204 patients), 4.0% (10 of 252), 4.3% (3
of 70), 26.1% (6 of 23), 21.6% (16 of 74), 20.0% (7 of
35) and 51.4% (18 of 35) for the minimum-risk, low-risk
1, low-risk 2, high-risk 1, high-risk 2, high-risk 3 and very
high-risk groups, respectively.
Confining the analysis to the patients with 24-h urinary
protein excretion data (n = 283), proteinuria of 0.69 g/day
or more was placed in the first tier and hypoalbuminaemia
in the second tier in most of the models with different con-
struction settings. Then, data of this subgroup were applied
to the final model constructed for the entire dataset replac-
ing dipstick proteinuria of 100 mg/dL with 24-h protein
excretion of 0.69 g/day. The model could similarly strat-
ify the patients according to the risk of renal deterioration:
actual incidences of substantial renal deterioration were
0% (0 of 72 patients), 4.0% (4 of 100), 4.8% (1 of 21),
25.0% (1 of 4), 14.3% (4 of 28), 15.8% (3 of 19) and 52.9%
Table 2. Risk of substantial deterioration in renal function: comparison
between risk groups
Risk group analysis Odds ratio (95% CI) P-value
Minimum versus
low 4.2 (0.94–19.0) 0.059
high 28.4 (6.7–121.5) <0.001
very high 106.9 (22.9–500.1) <0.001
Low versus
high 6.7 (3.4–13.4) <0.001
very high 25.2 (10.6–59.7) <0.001
High versus
very high 3.8 (1.7–8.2) 0.001
(9of17)fortheminimum-risk,low-risk1,low-risk2,high-
risk 1, high-risk 2, high-risk 3 and very high-risk groups,
respectively.
Evaluation of the decision tree model
The area under the ROC curve of the decision tree model
was 0.830 (95% CI, 0.777–0.883). We merged the low-risk
1 and 2 groups and high-risk 1, 2 and 3 groups because
their absolute frequency of renal deterioration was similar
(combined incidence, 4.0 and 22.0% in the low- and high-
risk groups, respectively). The OR of renal deterioration
between the very high- and minimum-risk groups reached
106.9 (95% CI, 22.9–500.1). Discrimination in deteriora-
tion risk was almost significant between any two of the risk
groups (Table 2).
By virtue of the 5-fold cross-validation, these six vari-
ables, especially the amount of proteinuria and the serum
albumin levels, were placed on a high tier in most of
the models, indicating the robustness of the model. The1246 M. Goto et al.
median value of the area under the ROC curve in the boot-
strap sample, the apparent performance, was 0.837 (IQR,
0.821–0.852) and that in the original sample with the de-
terioration risk evaluated in the bootstrap sample, the test
performance, was 0.827 (IQR, 0.825–0.828). The mean
value of the optimism, the difference between these perfor-
mances, was 0.013 [standard deviation (SD), 0.025]. Then,
theinternallyvalidatedperformancewasestimatedat0.824
(SD,0.023),whichwasclosetotheperformanceintheorig-
inal entire dataset (0.830).
Comparison with logistic regression model
Multivariable logistic regression identified the amount of
proteinuria, serum albumin levels and the presence of mild
haematuriaassignificantpredictorsofdeteriorationinrenal
function.Comparedwithnoortraceproteinuria,mild,mod-
erate and severe proteinuria were at greater risks of renal
deterioration [ORs, 2.8 (95% CI, 0.96–8.2), 6.8 (2.5–18.6)
and 14.4 (5.1–40.9), respectively]. ORs of serum albumin
<4.0 g/dL and the presence of mild haematuria (1–29 red
blood cells/high-power field) were 3.1 (95% CI, 1.7–5.6)
and 2.3 (95% CI, 1.2–4.3), respectively. The addition of 11
other predictors did not meaningfully increase the accuracy
of this model. The area under the ROC curve of the lo-
gistic regression model was 0.808 (95% CI, 0.754–0.861),
which was comparable to that of the decision tree model
(0.830).
Discussion
In order to facilitate clinical decision making for IgAN pa-
tients in busy clinical settings, clinicians need a practical
anduser-friendlytoolthatwouldrapidlyandaccuratelyesti-
mate the individual’s long-term renal outcome. The present
studyproposesanovelriskstratificationschemetoidentify
patients with IgAN who are at risk of substantial deterio-
ration in renal function during 10 years after beginning
follow-up using six basic clinical data, the severity of pro-
teinuria, serum albumin levels, mild haematuria, histologi-
calgradeofrenalbiopsy,diastolicbloodpressureandserum
total protein, obtained from routine examination for IgAN.
Among the patients whose overall incidence of substan-
tial renal deterioration was 8.9%, our decision tree model
can discriminate the risk from 1.0% to 51.4%. It had a
high validity because the internally validated performance
estimated by the bootstrap procedure was close to the per-
formance in the original entire dataset, and its accuracy
was somewhat better than that of the logistic regression
model.
The amount of proteinuria was one of the strongest pre-
dictors of renal outcome in IgAN patients in many previous
studies [5]. Semi-quantitative evaluation, which was not
recommended to quantify the amount of urinary protein
because of its urine concentration dependence [16], was
used in our main analysis because 24-h protein excretion
was not measured at baseline for two-thirds of the patients
followed. However, the subanalysis including only patients
with 24-h urinary protein excretion data yielded almost the
same performance of the decision tree model, indicating
the utility of spot urine in the prediction of renal outcome.
Our decision tree model placed histopathological grade
in the third tier under substantial proteinuria and hypoalbu-
minaemia. This agrees with a suggestion by Bartosik et al.
[17] that clinical features, suchas bloodpressureand sever-
ity of urinary protein excretion, appear to be stronger prog-
nostic indicators than histological findings. Even though
many histopathological classifications have been proposed
from different regions so far, no satisfying discriminators
were found and the debate continues. Even the most widely
adopted grading systems have several problems: severity of
tubulointerstitialchangesarenotclassifiedwithacleardef-
inition, active and chronic lesions are not interpreted sepa-
rately and the priority among each element such as cellular
proliferation, glomerulosclerosis, crescents and tubuloin-
terstitial damage is not mentioned [18,19]. Additionally,
reproducibility and interobserver reliability have not been
evaluatedformostoftheclassifications.Standardizationof
the histopathological findings will facilitate mutual under-
standing between nephrologists and pathologists in differ-
ent regions, resulting in the appropriate use of the grading
systems based on the scientific evidence in the clinical
settings.
Some potential limitations of the current analysis must
be acknowledged. Firstly, since information about treat-
ment was not obtained at baseline, we could not evaluate
theeffectsoftreatmentontheprognosisofIgAN.Secondly,
we had to exclude 491 patients because they did not have
serum creatinine data during the latter half of the follow-up
period,resultinginsubstantiallossofpower.Inordertocon-
struct an easily understandable prediction tool, we adopted
a decision tree induction algorithm that cannot handle cen-
sored cases. Thirdly, because only Japanese patients were
includedinthecurrentanalysis,applicabilityofthispredic-
tionmodeltootherpopulationswasnotverified.Therefore,
additional validation studies with different patient popula-
tions are warranted. Nonetheless, the current classification
tree analysis of the nationwide follow-up data of IgAN has
created a simple, robust, and highly discriminative tool to
predict progression of the disease.
In summary, in biopsy-proven IgAN patients without
substantial impairment of renal function, the risk of de-
terioration in renal function can be quickly estimated using
clinical information routinely examined for IgAN patients.
IgAN patients can be readily stratified into groups at min-
imum, low, high and very high risk for renal deterioration
during 10 years of follow-up, with the risks ranging from
1.0% to 51.4%. The accuracy of these estimates is com-
parable to that from the logistic regression model. This
decision tree model is a promising and useful prediction
tool in clinical settings.
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Complement deposition in renal histopathology of patients
with ANCA-associated pauci-immune glomerulonephritis
Min Chen, Guang-Qun Xing, Feng Yu, Gang Liu and Ming-Hui Zhao
Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University,
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing 100034, China
Abstract
Background. The pathogenesis of ANCA-associated
pauci-immune glomerulonephritis has not been fully elu-
cidated. Several studies had suggested that complement
deposition could be detected in renal histopathology. The
current study investigated the clinical and pathological sig-
nificanceofcomplementdepositioninrenalhistopathology
ofpatientswithANCA-associatedpauci-immuneglomeru-
lonephritis.
Methods. Renal biopsy specimens from 112 patients with
ANCA-associated pauci-immune glomerulonephritis were
Correspondence and offprint requests to: Ming-Hui Zhao, Renal Divi-
sion, Department of Medicine, Peking University First Hospital, Institute
of Nephrology,Peking University, Key Laboratoryof RenalDisease, Min-
istry of Health of China, Beijing 100034, China. Tel: +86-10-66551736;
Fax: +86-10-66551055; E-mail: mhzhao@bjmu.edu.cn
investigated using direct immunofluorescence, light and
electron microscopy. For direct immunofluorescence, IgG,
IgA,IgM,C3candC1qstainingonfreshfrozenrenaltissue
were routinely performed immediately after a renal biopsy.
Complement deposition was defined as the presence of
C3c or C1q for at least 1+ in a 0–4+ scale. Clinical and
histopathological data between patients with and without
complement deposition were compared.
Results. In direct immunofluorescence microscopy, C3c
and C1q could be detected in glomerular capillary wall
and/or mesangium in the specimens of 37/112 (33.0%),
7/112(6.3%)patients,respectively.Comparedwithpatients
without C3c deposition, patients with C3c deposition had a
higher level of urinary protein (P < 0.01) and poorer initial
renal function (P < 0.05).
Conclusion. Complement deposition was not rare in renal
histopathology of human ANCA-associated pauci-immune
C   The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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